This superior anti-metastatic activity is likely attributable to the combinatorial expression of CD40L, CD93, and CXCL13 and the promoter optimization of the LVV, which may enhance antigen presentation, T cell recruitment, and improved immune modulation in the tumor microenvironment. The gene discussed is CD93; the disease is neoplasm.